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Diabetes Mellitus (DM) can cause significant problems to the quality of life as it may increase 
the risk of complications. Dissatisfaction with therapy also contributes to its low effectiveness. 
Therapeutic satisfaction has an essential role in DM management, i.e., to optimize the effectiveness of 
the treatment. It is also believed to affect the decision-making process regarding patients‘ health-
related issues. A routine assessment of the satisfaction of DM patients is useful for health professionals 
in identifying the potential problems experienced by those who are in the middle of DM treatment. 
This study aimed to determine the relationship between patient satisfaction and effectiveness of 
insulin-based therapy for type 2 DM at Ulin Regional Public Hospital, Banjarmasin. This research is a 
nonexperimental study with a cross-sectional design. The data were collected prospectively with 
purposive sampling method from the type 2 DM patients at the Pharmacy Installation of Ulin Regional 
Public Hospital, Banjarmasin. While the therapeutic satisfaction data were obtained using the Patient 
Satisfaction with Insulin Therapy (PSIT) questionnaire, the effectiveness of the therapy was identified 
by examining the HbA1c values. Fifty-six (56) respondents participated and filled in the questionnaire, 
and the answers were processed with bivariate analysis, namely the chi-square test. The results showed 
that the respondents‘ satisfaction with the treatments was mostly on a medium level according to 33 
patients (58.9%). However, only 3.6% respondents found the therapy effective (HbA1c <6.5%). The 
remaining 96.4% thought that it was less effective in controlling diabetes. Based on the statistical 
analysis results, there is a significantly positive relationship between patient satisfaction and HbA1c 
value ([r= 0.828]; [p= 0.000]). There is also a significant positive relationship between patient 
satisfaction and the effectiveness of therapy in patients with type 2 diabetes at the Pharmacy 
Installation of Ulin Regional Public Hospital, Banjarmasin.  
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The World Health Organization (WHO) estimates that approximately 422 million adults 
developed Diabetes Mellitus (DM) in 2014. This number shows an increase from 108 million in 1980. 
DM and its complications pose significant economic damage for its sufferers, their families, health 
system, and the national economy due to the direct medical costs and loss of workability. ―Diabetes is 
a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction 
strategies beyond glycemic control‖ (American Diabetes Association (ADA), 2017, p. 51). 
International Diabetes Federation (IDF) predicts an increase in the number of people with DM in 
Indonesia from 9.1 million in 2014 to 14.1 million by 2035 (PERKENI, 2015a).  
Complications from DM are preventable by controlling blood glucose levels. However, 
achieving a target for glycemic control is not easy even if the patient has been taking Oral 
Hypoglycemic Drug (OHD) or insulin. DM management can be implemented with four pillars, 
including pharmacological intervention with, for instance, OHD and insulin therapy (ADA, 2017). 
Early application of insulin is useful for reducing glucose toxicity, mortality, and morbidity, improving 
endogenous insulin efficiency, and preventing damage to pancreatic beta cells (Tsukube et al., 2015). 
Endogenous insulin resistance can occur due to chronic weight gain, which reduces the insulin 
response. Therefore, early insulin treatment is vital (You et al., 2017). 
The many benefits of insulin treatment have led to its high application in DM therapy. However, 
there are some obstacles to its use including patients‘ fear of insulin injections, weight gain, and high 
cost. Even though earlier treatment may prevent immediate complications, these significant obstacles 
may cause patient dissatisfaction and noncompliance with the therapy. According to PERKENI 
(2015a), dissatisfaction and noncompliance, along with lack of knowledge about disease and 
treatment, contribute to low blood glucose control.  
Regular assessment of patient satisfaction with DM treatment can significantly assist health 
professionals to identify the potential problems experienced by patients with ongoing DM therapy. 
This satisfaction has an essential role in DM management, particularly for optimum blood glucose 
control. It is also believed to have an effect on the effectiveness of therapy in these patients. According 
to Boels et al. (2017), elevated HbA1c and controlled glycemic levels in DM patients are crucial in 
determining patient satisfaction with the treatment. 
 
RESEARCH METHOD 
This research is a non-experimental study with a cross-sectional design. The data were collected 
prospectively from type 2 DM patients that took insulin-based therapy at the Pharmacy Installation of 
Ulin Regional Public Hospital in Banjarmasin. The research subjects were determined using the 
following inclusion criteria: (1) male or female patients with type 2 DM who received either single or 
combination insulin therapy and (2) signed the informed consent to participate in the study. They were 
also selected based on an exclusion criterion, i.e., type 2 DM patients without HbA1c levels. Among 
the 93 subjects who met the inclusion criteria, 37 were excluded. The final total research subject was 
56 patients.  
 
Data and Tools 
The research instruments were a health assessment sheet containing patient medical history, 
Patient Satisfaction with Insulin Therapy (PSIT) questionnaire to measure the satisfaction with the 
therapy method, prescription, medical record, and laboratory examination result.  
 
Research Procedure 
The research procedure included directing the patients coming to the Polyclinic of Internal 
Medicine to meet the pharmacist after being examined by doctors. At the time of this meeting, they 
were provided with an explanation of the purpose of the meeting and asked for their willingness to 
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engage in the research. The willing patients were given informed consent. Afterward, they answered 
some general questions asked during the interviews and filled in the PSIT questionnaire to assess the 
degree of their satisfaction with the insulin-based type 2 DM treatment they were taking at Ulin 
Regional Public Hospital, Banjarmasin. The sampling was performed on type 2 DM patients who 
came for insulin-based therapy during May-August 2017. The data were identified and analyzed to 
provide an overview of patients‘ sociodemographic characteristics, types of therapy, and satisfaction 
with insulin therapy at Ulin Regional Public Hospital, Banjarmasin. The analysis attempted to 
determine the relationship between the duration of the disease, the type of therapy, and patient 
satisfaction, as well as the relationship between satisfaction with therapy and the HbA1c levels in 
patients with type 2 DM at Ulin Regional Public Hospital, Banjarmasin.  
 
Data Analysis 
The scale used to measure patient satisfaction with therapy was categorical, i.e., ordinal. The 
level satisfaction was defined based on mean and standard deviation into three categories, namely low 
(≤ mean-SD), medium (mean-SD < x ≤ mean+SD), and high (>mean+SD). Mean is the average score 
of the satisfaction of all respondents, SD is standard deviation, and x is the total score of each 
respondent‘s satisfaction. The measurement scale used for HbA1c was also categorical, i.e., ordinal. 
The categories were good (<6.5), medium (6.5-8), and poor (>8).  
The respondents' answers were collected and quantified based on the scores of the 
corresponding questions (scoring). These data were tabulated to facilitate the analysis. The univariate 
analysis aimed to describe the individual characteristics, the degree of satisfaction, compliance level, 
and HbA1c level statistically, i.e., the minimal and maximal value, mean, SD, and data frequency of 
each parameter. In this study, the chi-square test aimed to identify the relationship between patient 
satisfaction with therapy and HbA1c level. 
 
RESULTS AND DISCUSSION  
This study aimed to describe patient satisfaction and compliance with insulin-based type 2 DM 
therapy, as well as to identify the relationship between patient satisfaction and HbA1c level. It was 
performed prospectively to type 2 DM patients who received insulin-based therapy at the Pharmacy 
Installation of Ulin Regional Public Hospital in Banjarmasin from May to August 2017 (four months). 
These patients were selected as research subjects using purposive sampling method, and at the end of 
the study, fifty-six (56) respondents met the inclusion and exclusion criteria.  
The data of patient satisfaction and compliance with therapy were obtained from the 
questionnaire filled by the respondents. The patient satisfaction was based on the PSIT questionnaire. 
The sociodemographic data were collected from the health assessment sheet and interview with 
respondents. Meanwhile, the history of patient‘s therapy and HbA1c level were obtained from the 
clinical pathology laboratory. The descriptive analysis resulted in a set of data consisting of 
sociodemographic characteristics (i.e., age and sex), type of therapy, patient satisfaction, compliance 
with therapy, and HbA1c value. 
 
The characteristics of the respondents 
A descriptive analysis was used to provide an overview of the characteristics of the respondents 
by age, sex, and type of therapy. Respondents were grouped by type of therapy into those with single 
therapy category (i.e., respondents who used insulin alone) and the ones with combination therapy 
(i.e., respondents who combined insulin treatment with Oral Hypoglycemic Drugs (OHD)). 
Table I shows that most of the respondents (30 patients or 53.6%) are female, younger than 50 
years old (22 patients or 39.3%), and takes combination therapy (54 patients or 96.4%). The highest 
percentage of type 2 DM case in this study is found in patients aged 50-59 years old. In developing 
countries, the majority of type 2 DM patients is female (Migdalis et al., 2015), as affirmed in this 
research. According to Migdalis et al., (2015), the prevalence of type 2 DM in men is higher than in 
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women, but there are times when the contrary prevalence occurs. A higher prevalence of type 2 DM in 
women is specifically found in women with previous Gestational DM (ADA, 2017). 
 
Table I. The characteristics of respondents (Patients with type 2 DM) by age, sex, type of 








Male 26 46.4 
Female 30 53.4 
Age 
<50 years old 22 39.3 
50-59 years old 20 35.7 
60-69 years old 11 19.6 
≥70 years old 3 5.4 
Type of therapy 
Single 2 3.6 
Combination 54 96.4 
 
The incidence rate of type 2 DM varies between males and females. They have the same 
chance of developing DM. However, the risk factors dictate that women have a higher chance due to a 
higher increase of Body Mass Index (BMI). Hormonal process (i.e., premenstrual syndrome) in 
postmenopausal women accumulates body fat much quickly, which increases their risk to DM 
(Ramadhan and Marissa, 2015).  
Table II shows that most of the type 2 DM patients in this study are in combination therapy, 
while only a few of them takes single therapy. In addition to type of therapy, this table also lists the 
medicines used by patients with insulin-based type 2 DM therapy at the Pharmacy Installaion of Ulin 
Regional Public Hospital, Banjarmasin.  
Treatment with insulin is absolutely necessary for type 1 DM. Type 2 DM patients are 
prescribed with insulin during pregnancy, as well as when experiencing metabolic decompensation, 
receiving high dose steroid therapy, and planned to undergo surgery where lower blood glucose level 
is a requirement. DM patients with metabolic decompensation use insulin only if the patients 
experience the following cases: weight loss, Fasting Blood Glucose (FBC) >250 mg/dL, random blood 
glucose > 300 mg/dL, and HbA1c >9%, and if they have undergone therapy previously (PERKENI, 
2015b). 
According to Tsukube et al., (2015), patients receiving early and more aggressive treatment 
with insulin show better clinical outcomes especially related to glucotoxicity, which is presented by 
the improvement of pancreatic β cell function. Oral hyperglycemia drugs does not work quite 
efficiently in treating glucotoxicity in many type 2 DM patients. To achieve a desired treatment goal, 
the insulin regimen has to be adjusted to the needs and comforts of each patient. Rapid-acting insulin 
such as insulin aspart and lispro can produce higher levels of insulin serum and have a shorter duration 
of action. This type of insulin results in low postprandial glucose levels and reduces the duration of 
postprandial hyperglycemia significantly, which diminishes severe hypoglycemic events in type 2 DM 
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Single Premixed insulin 1 1.79% 






Long-acting insulin, Rapid-acting 
insulin 
25 44.64% 
Long-acting insulin, Metformin 4 7.14% 
Long-acting insulin, Acarbose 6 10.71% 
Long-acting insulin, Sulfonylureas 2 3.55% 
Premixed insulin, Sulfonylureas 1 1.79% 
Rapid-acting insulin, Long-acting 
insulin, Acarbose 
1 1.79% 
Rapid-acting insulin, Long-acting 
insulin, Metformin 
8 14.29% 
Long-acting insulin, Metformin, 
Acarbose 
1 1.79% 
Premixed insulin, Metformin, 
Acarbose 
1 1.79% 
Premixed insulin, Metformin, 
Thiazolidinedione 
1 1.79% 
Rapid-acting insulin, Long-acting 





Patient satisfaction with insulin-based therapy (PSIT) 
The PSIT questionnaire is one of the instruments used to measure the satisfaction of DM 
patients with insulin-based therapies. It analyzes the two critical contributing factors to patient 
satisfaction, namely convenience or ease of use and social comfort. 
Gerber et al., (2001) explain that PSIT questionnaire consists of 15 items of questions, and the 
responses to these questions are categorized using five-point Likert scale, namely strongly disagree, 
disagree, do not know, agree, and strongly agree. In this research, the categorization was performed 
and then summed into the overall value of the respondents‘ satisfaction. The mean±SD was then 
calculated from this value as a reference for classifying the degree of satisfaction. The results showed 
that the mean±SD was 53.57±12.88. The distribution of the satisfaction classification is presented in 
Table III.  
 
Table III. Respondents’ satisfaction with insulin-based therapy 
 





 Low 8 14.3 
 Medium 33 58.9 
 High 15 26.8 
 56 100 
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Table III shows that the respondents‘ satisfaction with their therapy was averagely medium. 
Black et al., (2006) also state that the PSIT questionnaire is divided into two subscales, namely 
convenience/ease of use and social satisfaction. With appropriate adjustments for positive and negative 
questions, such as No. 3 and 4, the sum of the Likert scores of all 15 questions can give an overall 
satisfaction score of 15-75. 
 
The HbA1c levels of the respondents 
Decreased HbA1c level has been proven to reduce microvascular complications in diabetic 
patients and is associated with a reduced risk of myocardial infarction and other fatal cardiovascular 
events. According to the American Diabetes Association (ADA), the recommended HbA1c level for 
adults with diabetes is <7.0%. Meanwhile, the American Association of Clinical Endocrinology 
(AACE), the American College of Endocrinology (ACE), and International Diabetes Federation (IDF) 
recommend HbA1c level of ≤6.5% (Karnchanasorn et al., 2016). 
This research used HbA1c as an instrument to represent the success of the therapy. HbA1c 
level examination is essential for DM patients to see their glycemic control. For most diabetic patients, 
the ideal target for HbA1c is below 7%. Any 1% decrease in HbA1c reduces the risk of microvascular 
complications by 40% and death by 21% (Bardisi et al., 2015). The results in Umpierrez et al. (2014) 
strongly recommend repeated therapies for patients with HbA1c of <7%. If the HbA1c level is 
between 7% and 9%, patients have to return to oral antidiabetic therapy and half of the basal insulin 
dose. Meanwhile, if the HbA1c level is > 9%, then they have to return to oral antidiabetic therapy and 
80% of the basal insulin dose. The HbA1c levels of the respondents are described in Table IV.  
Only 3.6% of 56 respondents were assumed to have a well-controlled glycemic level (HbA1c 
<6.5%), whereas the remaining 96.4% were categorized as not well-controlled. The low glycemic 
control in this study is similar to previous research where 85% of the respondents have HbA1c of less 
than 6.5% (Ramadhan and Marissa 2015). 
 







1 Good (<6,5%) 2 3.6 
2 Medium (6.5%-8%) 12 21.4 
3 Bad (>8%) 42 75.0 
Total 56 100 
 
To understand the relationship between patient satisfaction with the therapy and the HbA1c 
level, this research used bivariate analysis, i.e., chi-square test. As presented in Table V, there is a 
positive relationship between satisfaction, treatment method, and HbA1c level (r= 0.828). In another 
word, the higher the patient satisfaction, the better the HbA1c level. Referring to the r coefficient, 
there is a strong correlation between patient satisfaction and HbA1c level. High satisfaction with the 
therapy is always followed by a good HbA1c level. On the contrary, a low satisfaction leads to a bad 
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Table V. The relationship between patient satisfaction and effectiveness of therapy based on 













The results showed that respondents with high satisfaction certainly had a good HbA1c level, 
whereas the ones with low satisfaction had a bad HbA1c level. This finding is in line with Mora et al., 
(2017) where patient satisfaction and perception of the treatment are strongly related to compliance 
with therapy and the clinical outcome.  
According to Tsukube et al., (2015), aside from patient satisfaction and health status, a key to a 
successful therapy is a decrease in HbA1c level down to 7%. Therefore, the success of a DM treatment 
is strongly determined by a decrease of HbA1c level and early use of insulin.  
 
CONCLUSION 
There is a significant positive relationship between patient satisfaction with therapy and HbA1c 
level ([r= 0.828]; [p= 0.000]). 
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